Insmed (NASDAQ:INSM) Lowered to “Sell” at BidaskClub
Several other equities research analysts have also weighed in on INSM. Zacks Investment Research lowered Zynerba Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, May 11th. HC Wainwright reissued a buy rating and set a $52.00 price objective (up from $43.00) on shares of Insmed in a research note on Tuesday, April 9th. Finally, ValuEngine lowered Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $37.88.
INSM opened at $22.72 on Tuesday. The company has a debt-to-equity ratio of 2.48, a current ratio of 4.82 and a quick ratio of 4.69. The stock’s fifty day moving average is $24.86. Insmed has a fifty-two week low of $11.31 and a fifty-two week high of $33.13.
In other news, CEO William Lewis sold 400,000 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $26.00, for a total value of $10,400,000.00. Following the completion of the sale, the chief executive officer now owns 480,672 shares in the company, valued at $12,497,472. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 12,000 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $23.24, for a total value of $278,880.00. Following the completion of the sale, the insider now owns 36,350 shares of the company’s stock, valued at approximately $844,774. The disclosure for this sale can be found here. Company insiders own 4.95% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Strs Ohio purchased a new stake in shares of Insmed in the first quarter valued at $75,000. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Insmed in the fourth quarter valued at $101,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Insmed in the first quarter valued at $106,000. Millennium Management LLC purchased a new stake in shares of Insmed in the fourth quarter valued at $146,000. Finally, Amalgamated Bank purchased a new stake in shares of Insmed in the fourth quarter valued at $151,000.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Further Reading: What is the quiet period?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.